The regenerative medicine market size was valued at nearly USD 54.9 Bn in 2022 and is anticipated to reach USD 194.6 Bn by 2031, expanding at a CAGR of 15.1% during the forecast period, 2023-2031. Increasing research and development in tissue engineering and stem cell research in the regeneration of human tissues, cells, or organs to restore normal functioning is estimated to fuel the market.
Regenerative medicine aids in the repair of injured or dysfunctional tissue using stem cells and their derivatives. Cells are used in regenerative medicinal therapies. The natural ability of the human body to heal itself is the core principle of regenerative medicinal therapies.
Progenitor cell injection is implemented in regen medicine. It is done through secretion or individual administering of bioactive cell molecules and through the transplantation of laboratory grown tissues and organs. Regenerative medicine focuses on the development of novel treatments in healing organs and tissues without surgical procedures for restoring lost functions due to disease, aging, defects, or damage.
Chronic obstructive pulmonary disease, sports injuries, Parkinson’s disease, rheumatoid arthritis, spinal cord injuries, multiple sclerosis, osteoarthritis, systemic lupus erythematosus, and type 1 diabetes are some of the known diseases treated through regen medicine. Damaged or affected body parts with smooth muscle cells are known to have the greatest regenerative abilities.
The market report finds that the COVID-19 pandemic hampered the regenerative medicine industry due to reduced resources of manpower and logistics. CAR T-cell therapy procedures were affected due to reduced influx of patients during the government-imposed lockdowns. Clinical trial enrollments and research activities were significantly reduced by universities during the pandemic.
Regenerative Medicine Market Dynamics
Growing need in improving existing therapies for diabetes, cancer, musculoskeletal deformities, burns, and wounds through regen medicine to evade surgical procedures are driving the market. Developing a workforce with extensive knowledge to impart regenerative medicinal therapies is challenging for healthcare service providers.
Educating the existing workmen in respect of the evolving regenerative therapies is expensive and time consuming. High funding by governments worldwide in promoting research activities for gene therapies and cell therapies is expected to create lucrative opportunities in the regenerative medicine industry.
Scope of Regenerative Medicine Market Report
The global regenerative medicine market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Regenerative Medicine Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016 – 2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Product (Tissue Engineering [Hydrogels and Scaffolds], Gene Therapy, and Cell Therapy [Allogenic and Autologous]), and Application (Ophthalmology, Oncology, Cardiovascular, Wound Care, and Musculoskeletal)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Regenerative Medicine Market Size and Analysis, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Novartis AG; Cesca Therapeutics, Inc.; GlaxoSmithKline (GSK); U.S. Stem Cell, Inc.; Kite; Baxter International, Inc.; Boehringer Ingelheim; Stadler Rail AG Bayer AG; Pfizer, Inc.; Merck KGaA; Abbott; Vericel Corp.; Amgen Inc.; Bristol-Myers Squibb; AstraZeneca plc; Cook Biotech, Inc.; Bayer AG; F. Hoffmann-La Roche Ltd.; Integra Lifesciences Corp.; and Astellas Pharma, Inc
|
Regenerative Medicine Market Segment Insights
Product Segment Analysis
On the basis of product, the regenerative medicine industry is classified into tissue engineering, gene therapy, and cell therapy. The cell therapy segment is expected to dominate the market during the forecast period owing to the growing use of induced pluripotent stem cell therapies for repairing damaged cells by avoiding surgical procedures.
Stem cells derived from the bone marrow can be regenerated into other cell types for regenerating damaged tissues, which is anticipated to fuel the market. The tissue engineering segment is expected to expand exponentially in the coming years due to the growing use of healthcare 3D printing and organ-on-a-chip systems. Growing application of hydrogel and crosslinked hydrogel as scaffolds through lyophilization in tissue construction is anticipated to propel the market.
Application Segment Analysis
Based on the application, the market is divided into ophthalmology, oncology, cardiovascular, wound care, and musculoskeletal. The musculoskeletal segment is projected to hold a key share of the market, owing to the growing application of muscle-derived stem cells in the regeneration of skeletal muscles, bones, and skeletal muscles. Reduction in dependance on replacement procedures and pain-free delivery of threptic procedures is likely to boost the musculoskeletal segment in the coming years.
The cardiovascular segment is anticipated to expand significantly in the coming years owing to the potential of regenerative medicinal therapies in repairing, revascularizing, and repairing damaged heart tissue through cell-free therapy and stem cell therapies. Growing application of advanced biologics, gene therapies, and small molecules in stimulating the regeneration of damaged heart cells is likely to boost the segment in the coming years.
Regional Analysis
In terms of region, the global regenerative medicine market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period owing to the increasing flow of funds through government and private players. The presence of well-established information technology companies for accurate disease detection and prevention through technology frameworks are expected to propel the market in North America.
Asia Pacific is projected to grow at a rapid pace in the coming years, due to the presence of a large geriatric population and growing adoption of cell-based technology in preventive healthcare. Rising research in stem cell therapy procedures and the development of modern healthcare infrastructure are likely to propel the market in Asia Pacific.
Segments
The global regenerative medicine market has been segmented on the basis of
Product
- Tissue Engineering
- Gene Therapy
- Cell Therapy
Application
- Ophthalmology
- Oncology
- Cardiovascular
- Wound Care
- Musculoskeletal
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Novartis Pharmaceuticals Corporation
- Cesca Therapeutics, Inc.
- GSK plc
- U.S. Stem Cell, Inc.
- Kite
- Baxter International, Inc.
- Boehringer Ingelheim
- Stadler Rail AG Bayer AG
- Pfizer, Inc.
- Merck KGaA
- Abbott
- Vericel Corp.
- Amgen Inc.
- Bristol-Myers Squibb
- AstraZeneca plc
- Cook Biotech, Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Integra Lifesciences Corp.
- Astellas Pharma, Inc.
Competitive Landscape
Novartis AG; Cesca Therapeutics, Inc.; GlaxoSmithKline (GSK); U.S. Stem Cell, Inc.; Kite; Baxter International, Inc.; Boehringer Ingelheim; Stadler Rail AG Bayer AG; Pfizer, Inc.; Merck KGaA; Abbott; Vericel Corp.; Amgen Inc.; Bristol-Myers Squibb; AstraZeneca plc; Cook Biotech, Inc.; Bayer AG; F. Hoffmann-La Roche Ltd.; Integra Lifesciences Corp.; and Astellas Pharma, Inc. are some key players competing in the regenerative medicine market.
These companies engage in mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base and presence worldwide. The competitive landscape covers key insights into growth strategies adopted by major market players.
- In February, 2023, Kite completed the acquisition of Tmunity Therapeutics to boosted its pre-clinical and clinical programs through the inclusion of an ‘armored’ CAR T technology platform.
Request For Customization
Enquiry Before Buying
Speak With Analyst
